Related references
Note: Only part of the references are listed.Immunotherapy of Melanoma: Facts and Hopes
Sarah A. Weiss et al.
CLINICAL CANCER RESEARCH (2019)
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Erinna F. Lee et al.
CELL DEATH & DISEASE (2019)
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
The curcumin analog EF24 is a novel senolytic agent
Wen Li et al.
AGING-US (2019)
The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53
Esha Madan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
The Unfolded Protein Response and Cell Fate Control
Claudio Hetz et al.
MOLECULAR CELL (2018)
Piperlongumine Induces Apoptosis in Human Melanoma Cells Via Reactive Oxygen Species Mediated Mitochondria Disruption
Xuejiao Song et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2018)
Bioactivities of EF24, a Novel Curcumin Analog: A Review
Yonghan He et al.
FRONTIERS IN ONCOLOGY (2018)
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition
Ahmad Najem et al.
EUROPEAN JOURNAL OF CANCER (2017)
Effects of ursolic and oleanolic on SK-MEL-2 melanoma cells: In vitro and in vivo assays
Angela Caunii et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The non-canonical NF-κB pathway in immunity and inflammation
Shao-Cong Sun
NATURE REVIEWS IMMUNOLOGY (2017)
Mechanisms and Strategies to Overcome Resistance to Molecularly Targeted Therapy for Melanoma
Su Yin Lim et al.
CANCER (2017)
Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer
Xi Chen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Antibody-Targeted Chemotherapy for the Treatment of Melanoma
Wendy K. Nevala et al.
CANCER RESEARCH (2016)
The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
Alex Kim et al.
EXPERT OPINION ON DRUG DISCOVERY (2016)
Curcumin: A new candidate for melanoma therapy?
Hamed Mirzaei et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer
Weiqian Chen et al.
REDOX BIOLOGY (2016)
The Multifaceted Role of Curcumin in Cancer Prevention and Treatment
Muthu K. Shanmugam et al.
MOLECULES (2015)
Plant natural products: from traditional compounds to new emerging drugs in cancer therapy
L. Ouyang et al.
CELL PROLIFERATION (2014)
Review of Natural Compounds for Potential Skin Cancer Treatment
Tawona N. Chinembiri et al.
MOLECULES (2014)
A Review on Antibacterial, Antiviral, and Antifungal Activity of Curcumin
Soheil Zorofchian Moghadamtousi et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
Alexander Roesch et al.
CANCER CELL (2013)
The Curcumin Analog EF24 Targets NF-κB and miRNA-21, and Has Potent Anticancer Activity In Vitro and In Vivo
Chuan He Yang et al.
PLOS ONE (2013)
Challenging resistance mechanisms to therapies for metastatic melanoma
Lucio Tentori et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
Birgit O. Engesaeter et al.
CANCER BIOLOGY & THERAPY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Epidemiology of invasive cutaneous melanoma
R. M. MacKie et al.
ANNALS OF ONCOLOGY (2009)
The Classification of Cutaneous Melanoma
Lyn McDivitt Duncan
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
The NF-κB Family of Transcription Factors and Its Regulation
Andrea Oeckinghaus et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2009)
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature
Preetha Anand et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Antioxidant and radical scavenging properties of curcumin
Tuba Ak et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2008)
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Inhibition of IκB kinase-nuclear factor-κB signaling pathway by 3,5-bis(2-flurobenzylidene) piperidin-4-one (EF24), a novel monoketone analog of curcumin
Andrea L. Kasinski et al.
MOLECULAR PHARMACOLOGY (2008)
Silencing livin gene by siRNA leads to apoptosis induction, cell cycle arrest, and proliferation inhibition in malignant melanoma LiBr cells
Hao Wang et al.
ACTA PHARMACOLOGICA SINICA (2007)
Overcoming apoptosis deficiency of melanoma - Hope for new therapeutic approaches
Juergen Eberle et al.
DRUG RESISTANCE UPDATES (2007)
Bioavailability of curcumin: Problems and promises
Preetha Anand et al.
MOLECULAR PHARMACEUTICS (2007)
New aspects of natural products in drug discovery
Kin S. Lam
TRENDS IN MICROBIOLOGY (2007)
Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin
Constantin Tamvakopoulos et al.
CLINICAL CANCER RESEARCH (2007)
Bis(2-hydroxybenzylidene) acetone, a potent inducer of the phase 2 response, causes apoptosis in mouse leukemia cells through a p53-independent, caspase-mediated pathway
Albena T. Dinkova-Kostova et al.
CANCER LETTERS (2007)
Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy
Hong Chang et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
KSM Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Multiple biological activities of curcumin: A short review
RK Maheshwari et al.
LIFE SCIENCES (2006)
The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress
AS Lee
METHODS (2005)
EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism
BK Adams et al.
ANTI-CANCER DRUGS (2005)
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents
BK Adams et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Natural products in the process of finding new drug candidates
P Vuorela et al.
CURRENT MEDICINAL CHEMISTRY (2004)
NF-κB-mediated IAP expression induces resistance of intestinal epithelial cells to apoptosis after polyamine depletion
TT Zou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2004)
Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy
JC Schmollinger et al.
APOPTOSIS (2004)
Apoptosis and melanoma chemoresistance
MS Soengas et al.
ONCOGENE (2003)
Death and anti-death: Tumour resistance to apoptosis
FH Igney et al.
NATURE REVIEWS CANCER (2002)
Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer
SD Catz et al.
ONCOGENE (2001)
Pure compound libraries; a new perspective for natural product based drug discovery
KU Bindseil et al.
DRUG DISCOVERY TODAY (2001)
ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas
D Vucic et al.
CURRENT BIOLOGY (2000)
Share Paper
